-
公开(公告)号:US06872735B2
公开(公告)日:2005-03-29
申请号:US10618178
申请日:2003-07-11
申请人: Daniel J. Burdick , Mark S. Stanley , David Oare , Mark E. Reynolds , Thomas R. Gadek , James C. Marsters
发明人: Daniel J. Burdick , Mark S. Stanley , David Oare , Mark E. Reynolds , Thomas R. Gadek , James C. Marsters
IPC分类号: C07D277/06 , A61K31/197 , A61K31/198 , A61K31/341 , A61K31/351 , A61K31/385 , A61K31/40 , A61K31/4015 , A61K31/4025 , A61K31/403 , A61K31/426 , A61K31/427 , A61K31/44 , A61K31/445 , A61K31/4458 , A61K31/4462 , A61K31/4465 , A61K31/4525 , A61P1/04 , A61P11/06 , A61P17/06 , A61P19/02 , A61P29/00 , A61P37/06 , C07C233/83 , C07D207/16 , C07D211/60 , C07D211/62 , C07D307/54 , C07D405/12 , C07D407/12 , C07D409/12 , C07D417/12
CPC分类号: C07D405/12 , A61K31/198 , A61K31/40 , A61K31/44 , C07D207/16 , C07D277/06 , C07D307/54 , C07D417/12
摘要: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
摘要翻译: 本发明涉及具有式(I)的新化合物,其中Cy,X,Y,L和R1-6如本文所定义。 这些化合物结合CD11 / CD18粘附受体如淋巴细胞功能相关抗原-1(LFA-1),因此可用于治疗由LFA-1介导的疾病如炎症和自身免疫性疾病。
-
公开(公告)号:US06667318B2
公开(公告)日:2003-12-23
申请号:US09994546
申请日:2001-11-26
申请人: Daniel J. Burdick , Mark S. Stanley , David Oare , Mark E. Reynolds , Thomas R. Gadek , James C. Marsters
发明人: Daniel J. Burdick , Mark S. Stanley , David Oare , Mark E. Reynolds , Thomas R. Gadek , James C. Marsters
IPC分类号: A61K314525
CPC分类号: C07D405/12 , A61K31/198 , A61K31/40 , A61K31/44 , C07D207/16 , C07D277/06 , C07D307/54 , C07D417/12
摘要: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
摘要翻译: 本发明涉及具有式(I)的新化合物,其中Cy,X,Y,L和R1-6如本文所定义。 这些化合物结合CD11 / CD18粘附受体如淋巴细胞功能相关抗原-1(LFA-1),因此可用于治疗由LFA-1介导的疾病如炎症和自身免疫性疾病。
-
公开(公告)号:US20100144732A1
公开(公告)日:2010-06-10
申请号:US12520194
申请日:2007-12-13
IPC分类号: A61K31/5377 , A61K31/505 , C07D413/02 , C07D239/02 , A61P35/04
CPC分类号: C07D239/48
摘要: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein Q, X, Y, Z, R1, R2, R4, m and n are as defined herein.
摘要翻译: 本发明提供新的激酶抑制剂,其可用作例如治疗恶性肿瘤的治疗剂,其中化合物具有通式I,其中Q,X,Y,Z,R 1,R 2,R 4,m和n如本文所定义。
-
公开(公告)号:US20080318989A1
公开(公告)日:2008-12-25
申请号:US12097030
申请日:2006-12-15
申请人: Daniel J. Burdick , Jun Liang
发明人: Daniel J. Burdick , Jun Liang
IPC分类号: A61K31/506 , C07D239/24 , C12N5/00 , A61P35/00
CPC分类号: C07D403/12 , C07D409/12 , C07D413/12
摘要: The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I) wherein ring A, X, Y, Z, R1, R2, R3, R4, m and n are as defined herein.
摘要翻译: 本发明提供新的激酶抑制剂,其可用作例如治疗恶性肿瘤的治疗剂,其中化合物具有通式(I),其中环A,X,Y,Z,R 1,R 2,R 3,R 4,m和n为 如本文所定义。
-
-
-